Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma remains a prominent cause of cancer-related mortality globally. Transarterial yttrium-90 radioembolization is a versatile therapy and plays an important role in the treatment of hepatocellular carcinoma. This review summarizes the establishment of radioembolization in the hepatocellular carcinoma treatment paradigm, treatment considerations across cancer stages, and recent advances in evidence.

Keywords

Hepatocellular carcinoma / radioembolization / yttrium-90 / dosimetry / radiation segmentectomy

References

[1] Jemal A,Johnson CJ.Annual report to the nation on the status of cancer, 1975-2014, featuring survival.J Natl Cancer Inst2017;109 PMCID:PMC5409140

[2] Siegel R,Zou Z.Cancer statistics, 2014.CA Cancer J Clin2014;64:9-29

[3] Kulik L.Criteria for liver transplantation in hepatocellular carcinoma.Clin Liver Dis (Hoboken)2015;6:100-2 PMCID:PMC6490853

[4] Villanueva A.Hepatocellular carcinoma.N Engl J Med2019;380:1450-62

[5] Llovet JM,Bruix J.Prognosis of hepatocellular carcinoma: the BCLC staging classification.Semin Liver Dis1999;19:329-38

[6] Llovet JM,Bruix J.Panel of Experts in HCC-Design Clinical TrialsDesign and endpoints of clinical trials in hepatocellular carcinoma.J Natl Cancer Inst2008;100:698-711

[7] Benson AB,Abbott DE.Hepatobiliary cancers, version 2.2021, NCCN Clinical practice guidelines in oncology.J Natl Compr Canc Netw2021;19:541-65

[8] Salem R,Mouli S.Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma.Gastroenterology2016;151:1155-63.e2 PMCID:PMC5124387

[9] Lewandowski RJ,Abouchaleh N.Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma.Radiology2018;287:1050-8

[10] Padia SA,Horton KJ.Segmental yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study.J Vasc Interv Radiol2017;28:777-85.e1

[11] Riaz A,Atassi B.Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization.Int J Radiat Oncol Biol Phys2011;79:163-71

[12] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases.Hepatology2018;68:723-50

[13] European Association for the Study of the Liver. Electronic address: [e-mail]., European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[14] Llovet JM,Montaña X.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.Lancet2002;359:1734-9

[15] Lo CM,Tso WK.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.Hepatology2002;35:1164-71

[16] Sangro B,Cianni R.European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY)Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.Hepatology2011;54:868-78

[17] Kallini JR,Salem R.Transarterial radioembolization with yttrium-90 for the treatment of hepatocellular carcinoma.Adv Ther2016;33:699-714 PMCID:PMC4882351

[18] Tong AK,Too CW,Ng DC.Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry.Br J Radiol2016;89:20150943 PMCID:PMC5258157

[19] Walker LA.Radioactive yttrium 90: a review of its properties, biological behavior, and clinical uses.Acta Radiol Ther Phys Biol1964;2:302-14

[20] Kennedy A,Salem R.Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.Int J Radiat Oncol Biol Phys2007;68:13-23

[21] Salem R,Lam M.Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group.Eur J Nucl Med Mol Imaging2019;46:1695-704

[22] Park W,Paik SW.Local radiotherapy for patients with unresectable hepatocellular carcinoma.Int J Radiat Oncol Biol Phys2005;61:1143-50

[23] Kim TH,Park JW.Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy.Int J Radiat Oncol Biol Phys2007;67:225-31

[24] Son SH,Jo IY.Significance of an increase in the Child-Pugh score after radiotherapy in patients with unresectable hepatocellular carcinoma.Radiat Oncol2014;9:101 PMCID:PMC4016647

[25] Vouche M,Ward TJ.Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy.Hepatology2014;60:192-201

[26] Garin E,Guiu B.Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial.Lancet Gastroenterol Hepatol2021;6:17-29

[27] Kappadath SC,Balagopal A,Kaseb A.Hepatocellular carcinoma tumor dose response after ⁹⁰Y-radioembolization with glass microspheres using ⁹⁰Y-SPECT/CT-based voxel dosimetry.Int J Radiat Oncol Biol Phys2018;102:451-61

[28] Song YS,Kim HC.PET/CT-based dosimetry in 90Y-microsphere selective internal radiation therapy: single cohort comparison with pretreatment planning on (99m)Tc-MAA imaging and correlation with treatment efficacy.Medicine (Baltimore)2015;94:e945 PMCID:PMC4616469

[29] Chan KT,Johnson GE.Prospective trial using internal pair-production positron emission tomography to establish the yttrium-90 radioembolization dose required for response of hepatocellular carcinoma.Int J Radiat Oncol Biol Phys2018;101:358-65

[30] Gabr A,Johnson GE.Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants.Eur J Nucl Med Mol Imaging2021;48:580-3

[31] Gil-Alzugaray B,Iñarrairaegui M.Prognostic factors and prevention of radioembolization-induced liver disease.Hepatology2013;57:1078-87

[32] Riaz A,Kulik LM.Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review.J Vasc Interv Radiol2009;20:1121-30; quiz 1131

[33] Sangro B,Bester L.Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review.Hepatology2017;66:969-82

[34] De la Garza-Ramos C,Montazeri SA.Biochemical safety of ablative yttrium-90 radioembolization for hepatocellular carcinoma as a function of percent liver treated.J Hepatocell Carcinoma2021;8:861-70 PMCID:PMC8335548

[35] Biederman DM,Bishay VL.Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study.Radiology2017;283:895-905

[36] Salem R,Kim E.Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study.Hepatology2021;74:2342-52 PMCID:PMC8596669

[37] Arndt L,Wagstaff W.Evaluation of medium-term efficacy of Y90 radiation segmentectomy vs percutaneous microwave ablation in patients with solitary surgically unresectable < 4 cm hepatocellular carcinoma: a propensity score matched study.Cardiovasc Intervent Radiol2021;44:401-13

[38] Toskich B,Olson MT.Pathologic response of hepatocellular carcinoma treated with yttrium-90 glass microsphere radiation segmentectomy prior to liver transplantation: a validation study.J Vasc Interv Radiol2021;32:518-26.e1

[39] Lu DS,Limanond P.Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors.J Vasc Interv Radiol2003;14:1267-74

[40] Lam VW,Chok KS.Incomplete ablation after radiofrequency ablation of hepatocellular carcinoma: analysis of risk factors and prognostic factors.Ann Surg Oncol2008;15:782-90

[41] Padia SA,Roudsari B,Coveler A.Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.J Vasc Interv Radiol2014;25:1067-73

[42] Salem R,Butt Z.Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization.Clin Gastroenterol Hepatol2013;11:1358-65.e1

[43] Salem R,Kulik L.Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.Gastroenterology2011;140:497-507.e2 PMCID:PMC3129335

[44] Casadei Gardini A, Tamburini E, Iñarrairaegui M, Frassineti GL, Sangro B. Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials.Onco Targets Ther2018;11:7315-21 PMCID:PMC6207245

[45] Salem R,Riaz A.Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.Hepatology2018;68:1429-40

[46] Garin E,Edeline J.Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.J Nucl Med2015;56:339-46

[47] Garin E,Pracht M.High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with ⁹⁰Y-loaded glass microsphere radioembolization.Liver Int2017;37:101-10

[48] Vilgrain V,Assenat E.Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.Lancet Oncol2017;18:1624-36

[49] Chow PKH,Tan SB.Asia-Pacific Hepatocellular Carcinoma Trials GroupSIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma.J Clin Oncol2018;36:1913-21

[50] Yao FY,Nikolai B.A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.Liver Transpl2003;9:684-92

[51] Llovet JM,Castells A.Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.Hepatology1999;29:62-7

[52] Halazun KJ,Rana AA.Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment.Hepatology2014;60:1957-62

[53] Heimbach JK,Finn RS.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[54] Biederman DM,Korff RA.Radiation segmentectomy versus selective chemoembolization in the treatment of early-stage hepatocellular carcinoma.J Vasc Interv Radiol2018;29:30-7.e2

[55] Tohme S,Chen HW.Yttrium-90 radioembolization as a bridge to liver transplantation: a single-institution experience.J Vasc Interv Radiol2013;24:1632-8

[56] Ettorre GM,Laurenzi A.Yttrium-90 radioembolization for hepatocellular carcinoma prior to liver transplantation.World J Surg2017;41:241-9

[57] Gabr A,Ali R.Comparative study of post-transplant outcomes in hepatocellular carcinoma patients treated with chemoembolization or radioembolization.Eur J Radiol2017;93:100-6

[58] Gabr A,Mouli S.Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort.Hepatology2021;73:998-1010

[59] Agopian VG,McWilliams J.Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.Ann Surg2015;262:536-45; discussion 543-5

[60] Gordon-Weeks AN,Petrinic T,Burls A.Systematic review of outcome of downstaging hepatocellular cancer before liver transplantation in patients outside the Milan criteria.Br J Surg2011;98:1201-8

[61] Parikh ND,Singal AG.Downstaging hepatocellular carcinoma: a systematic review and pooled analysis.Liver Transpl2015;21:1142-52

[62] Lewandowski RJ,Riaz A.A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.Am J Transplant2009;9:1920-8

[63] Jakobs TF,Atassi B.Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres.Dig Dis Sci2008;53:2556-63

[64] Kubota K,Kusaka K.Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors.Hepatology1997;26:1176-81

[65] Vouche M,Atassi R.Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.J Hepatol2013;59:1029-36 PMCID:PMC5085290

[66] Gaba RC,Kulik LM.Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization.Ann Surg Oncol2009;16:1587-96

[67] van Lienden KP,de Graaf W.Portal vein embolization before liver resection: a systematic review.Cardiovasc Intervent Radiol2013;36:25-34 PMCID:PMC3549243

[68] Padia SA,Johnson GE.Society of Interventional Radiology Standards of Practice CommitteeRadioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions.J Vasc Interv Radiol2017;28:1-15

[69] Riaz A,Salem R.Side effects of yttrium-90 radioembolization.Front Oncol2014;4:198 PMCID:PMC4114299

[70] Sangro B,Rodriguez J.Liver disease induced by radioembolization of liver tumors: description and possible risk factors.Cancer2008;112:1538-46

[71] Kennedy AS,Dezarn WA.Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors.Int J Radiat Oncol Biol Phys2009;74:1494-500

[72] Collins J.Hepatic radioembolization complicated by gastrointestinal ulceration.Semin Intervent Radiol2011;28:240-5 PMCID:PMC3193333

[73] Bester L,Pocock N.Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients.J Vasc Interv Radiol2012;23:96-105

[74] Ayav A,Jiao LR.Portal hypertension secondary to 90Yttrium microspheres: an unknown complication.J Clin Oncol2005;23:8275-6

[75] Ricke J,Amthauer H.Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.J Hepatol2019;71:1164-74